E. Jane Leonard

954 total citations
24 papers, 415 citations indexed

About

E. Jane Leonard is a scholar working on Oncology, Cell Biology and Molecular Biology. According to data from OpenAlex, E. Jane Leonard has authored 24 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Cell Biology and 10 papers in Molecular Biology. Recurrent topics in E. Jane Leonard's work include Microtubule and mitosis dynamics (11 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (5 papers). E. Jane Leonard is often cited by papers focused on Microtubule and mitosis dynamics (11 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (5 papers). E. Jane Leonard collaborates with scholars based in United States, Belgium and Japan. E. Jane Leonard's co-authors include Xiaofei Zhou, Howard Fingert, Daniel O. Persky, Jonathan W. Friedberg, Steven H. Bernstein, Hadi Danaee, Izidore S. Lossos, Daruka Mahadevan, Amit B. Agarwal and Richard Burack and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

E. Jane Leonard

23 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Jane Leonard United States	10	206	166	154	116	77	24	415
Amit B. Agarwal United States	6	203 1.0×	238 1.4×	71 0.5×	100 0.9×	123 1.6×	10	429
Ruta Grebliunaite United States	5	117 0.6×	332 2.0×	74 0.5×	47 0.4×	58 0.8×	6	623
Seeta R. Chaganti United States	10	188 0.9×	210 1.3×	40 0.3×	245 2.1×	146 1.9×	14	521
Yoshiaki Chinen Japan	14	143 0.7×	291 1.8×	25 0.2×	134 1.2×	58 0.8×	49	513
Christian Hurtz United States	10	115 0.6×	246 1.5×	69 0.4×	47 0.4×	107 1.4×	32	607
G Wong United States	8	163 0.8×	106 0.6×	14 0.1×	182 1.6×	121 1.6×	10	391
Thomas F.E. Barth Germany	8	151 0.7×	81 0.5×	16 0.1×	240 2.1×	135 1.8×	9	361
J Schwaller Switzerland	8	170 0.8×	210 1.3×	19 0.1×	90 0.8×	40 0.5×	10	378
Hui‐Jen Tsai Taiwan	10	207 1.0×	135 0.8×	22 0.1×	21 0.2×	18 0.2×	16	425
S H Swerdlow United States	6	226 1.1×	103 0.6×	12 0.1×	283 2.4×	171 2.2×	8	412

Countries citing papers authored by E. Jane Leonard

Since Specialization

Citations

This map shows the geographic impact of E. Jane Leonard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Jane Leonard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Jane Leonard more than expected).

Fields of papers citing papers by E. Jane Leonard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Jane Leonard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Jane Leonard. The network helps show where E. Jane Leonard may publish in the future.

Co-authorship network of co-authors of E. Jane Leonard

This figure shows the co-authorship network connecting the top 25 collaborators of E. Jane Leonard. A scholar is included among the top collaborators of E. Jane Leonard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Jane Leonard. E. Jane Leonard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diamond, Jennifer R., Jason T. Henry, Gerald S. Falchook, et al.. (2022). Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors. Cancer Research. 82(12_Supplement). CT249–CT249. 7 indexed citations

Diamond, Jennifer R., Jason T. Henry, Gerald S. Falchook, et al.. (2022). Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2690–TPS2690. 17 indexed citations

Lim, Bora, David A. Potter, Mohamad A. Salkeni, et al.. (2021). Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 27(12). 3329–3338. 12 indexed citations

Franklin, Anna R., Mara Albonei Dudeque Pianovski, Franca Fagioli, et al.. (2021). AN OPEN‐LABEL, PHASE 1/2 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE IN PAEDIATRIC PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA. Hematological Oncology. 39(S2). 2 indexed citations

Matloub, Yousif, Lia Gore, Mignon L. Loh, et al.. (2020). A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood. 136(Supplement 1). 47–47.

Diamond, Jennifer R., David A. Potter, Paula Silverman, et al.. (2019). Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus. Cancer Research. 79(4_Supplement). PD1–9. 3 indexed citations

Owonikoko, Taofeek K., Kristiaan Nackaerts, Tibor Csőszi, et al.. (2017). OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 12(1). S261–S262. 17 indexed citations

Nackaerts, K., Tibor Csőszi, Gyula Ostoros, et al.. (2016). Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC). Annals of Oncology. 27. vi493–vi493. 11 indexed citations

Graff, Julie N., Celestia S. Higano, Noah M. Hahn, et al.. (2016). Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors. Cancer. 122(16). 2524–2533. 29 indexed citations

10.

Goldberg, Stuart L., Pierre Fenaux, Michael Craig, et al.. (2014). An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leukemia Research Reports. 3(2). 58–61. 66 indexed citations

11.

Özcan, Muhıt, Andrei R. Shustov, Xiaofei Zhou, et al.. (2014). Trial in Progress: Phase 3 Randomized Study of Investigational Drug Alisertib (Mln8237) Vs Investigator'S Choice in Patients (Pts) with Relapsed/Refractory (Rel/Ref) Peripheral T-Cell Lymphoma (Ptcl): the Lumiere Trial. Annals of Oncology. 25. iv339–iv339. 1 indexed citations

12.

Sarantopoulos, John, Noah M. Hahn, Celestia S. Higano, et al.. (2014). Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 32(4_suppl). 217–217. 3 indexed citations

13.

Friedberg, Jonathan W., Daruka Mahadevan, Daniel O. Persky, et al.. (2013). Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 32(1). 44–50. 161 indexed citations

14.

Kelly, Kevin R., Daniel O. Persky, Daruka Mahadevan, et al.. (2013). Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood. 122(21). 3027–3027. 7 indexed citations

15.

O’Connor, Owen A., E. Jane Leonard, & Ely Benaim. (2012). Phase III study of investigational MLN8237 (alisertib) versus investigator’s choice in patients (pts) with relapsed/refractory (rel/ref) peripheral T-cell lymphoma (PTCL).. Journal of Clinical Oncology. 30(15_suppl). TPS8110–TPS8110. 4 indexed citations

16.

Persky, Daniel O., Kevin R. Kelly, Peter P. Lee, et al.. (2012). Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL).. Journal of Clinical Oncology. 30(15_suppl). TPS8109–TPS8109. 2 indexed citations

17.

Hahn, Noah M., John Sarantopoulos, Celestia S. Higano, et al.. (2012). MLN8237 (ALISERTIB), An Investigational Aurora a Kinase (AAK) Inhibitor, in Patients with Advanced Solid Tumors Including Castration-Resistant Prostate Cancer (CRPC) Receiving a Standard Docetaxel Regimen: Preliminary Phase 1 Results. Annals of Oncology. 23. ix303–ix304. 1 indexed citations

18.

Benaim, Ely, Xiaofei Zhou, Hua Liu, et al.. (2012). Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors. Blood. 120(21). 3683–3683. 3 indexed citations

19.

Friedberg, Jonathan W., Daruka Mahadevan, JungAh Jung, et al.. (2011). Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL). Blood. 118(21). 95–95. 34 indexed citations

20.

Leonard, E. Jane, et al.. (1983). N-formylmethionyl-leucyl-[3H]phenylalanine binding, superoxide release, and chemotactic responses of human blood monocytes that repopulate the circulation during leukapheresis. Blood. 62(4). 918–923. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact